Interpace Biosciences Announces U.S. PTO Issuance of Patent No. 11,143,657 Titled: Topographic Genotyping for Determining the Diagnosis, Malignant Potential, and Biologic Behavior of Pancreatic Cysts and Related Conditions
October 28, 2021 08:15 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant...
Interpace Diagnostics Labs Receive College of American Pathology (CAP) Accreditation
April 25, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Pennsylvania and Connecticut Labs Both Receive Accreditation PARSIPPANY, NJ, April 25, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has...
Interpace Diagnostics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement
July 31, 2018 08:30 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, July 31, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that...